Propranolol in the Treatment of Infantile Hemangiomas: A Single-CenterExperience
DOI:
https://doi.org/10.5644/ama2006-124.502Keywords:
Infantile Hemangioma, Propranolol, Pediatric, Vascular TumorAbstract
Objective. Infantile hemangiomas (IH) are common benign vascular tumors of infancy that typically undergo gradual spontaneous regression over several years, although a minority require treatment. Propranolol, a non-selective β-adrenergic antagonist, is the first-line therapy for complicated or high-risk IH, demonstrating both efficacy and a favorable safety profile.
Materials and Methods. We retrospectively analyzed 37 infants treated with oral propranolol at a single center. Patients were monitored in-hospital during treatment initiation and at regular, outpatient visits. The response was assessed using clinical measurements, ultrasonography, and standardized photographs.
Results. Most patients had solitary lesions predominantly located in the head region. Complete regression occurred in 26 patients (70.3%) and partial regression in 11 (29.7%). Treatment duration ranged from 2 to 24 months (mean 10.1 months). Adverse events were rare and mild, including one case of hypoglycemia and one of transient somnolence.
Conclusion. Oral propranolol is a safe and effective first-line therapy for IH, particularly when initiated early during the proliferative phase.
References
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735-46. doi: 10.1056/NEJMoa1404710.
Hoeger PH, Harper JI, Baselga E, Bonnet D, Boon LM, Ciofi Degli Atti M, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855-65. doi: 10.1007/s00431-015-2570-0.
Tan X, Guo S, Wang C. Propranolol in the Treatment of Infantile Hemangiomas. Clin Cosmet Investig Dermatol. 2021;14:1155-63. doi: 10.2147/CCID.S332625.
Roganović J, Kolombo I. Dojenačkihemangiomi. [Infantile hemangiomas]. Medicina Fluminensis. 2016;52(4):444-51. doi:10.21860/medflum2016_4ro2. [in Croatian].
Storch CH, Hoeger PH. Propranolol for infantile hemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163:269–274. doi:.1111/j.1365-2133.2010.09848.x.
Han K, Wei J, Zheng H, Li X, Zhang A, Ma Y, et al. Efficacy and safety of oral propranolol or topical timolol for the treatment of superficial infantile hemangiomas. J Craniofac Surg. 2024;35(3):e254-7. doi: 10.1097/
SCS.0000000000010001.
Meza Viteri V, Aranibar L. Oral atenolol compared to oral propranolol for infantile hemangioma. Medwave. 2023;23(11):e2753. English, Spanish. doi: 10.5867/medwave.2023.11.2753.
Izadpanah A, Izadpanah A, Kanevsky J, Belzile E, Schwarz K. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and metaanalysis. Plast Reconstr Surg. 2013;131(3):601-13. doi: 10.1097/PRS.0b013e31827c6fab.
Fei Q, Lin Y, Chen X. Treatments for infantile Hemangioma: A systematic review and network meta-analysis. EClinicalMedicine. 2020;26:100506. doi: 10.1016/j.eclinm.2020.100506.
Downloads
Published
License
Copyright (c) 2026 Jelena Roganović, Andrea Kevrić, Ana Đorđević
This work is licensed under a Creative Commons Attribution 4.0 International License.
